neurotensin
Peptideexperimental
Neurotensin is a 13 amino acid neuropeptide that is implicated in the regulation of luteinizing hormone and prolactin release and has significant interaction with the dopaminergic system. Neurotensin was first isolated from extracts of bovine hypothalamus based on its ability to cause a visible vasodilation in the exposed cutaneous regions of anesthetized rats. — Wikipedia
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 5, 2018 (NCT03522792)
Timeline
No events for the selected filters.
Mechanism of action
- Neurotensin receptorAGONIST
Neurotensin receptor agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaNeurotensin ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04179331 | N/A | Dec 31, 2019 | University of Copenhagen |
| NCT04186026 | N/A | Oct 1, 2019 | University of Copenhagen |
| NCT03522792 | N/A | Jan 5, 2018 | University of Copenhagen |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| University of Copenhagen | Academic/Hospital | 3 | 3 | 1 | 2018 |
1 organizations
Page 1 / 1